p38 MAPK in pancreatic cancer: finding a protective needle in the haystack.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25135483.
- Also identified by DOI 10.1158/1078-0432.CCR-14-1543 and PMC identifier 4254114.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Activated p38 MAPK alpha (pp38α) is a good prognostic marker in pancreatic ductal adenocarcinoma that could be used to personalize therapy. pp38α suppresses JNK-mediated proliferation, both in vitro and in vivo. These findings support the testing of combination therapies that include JNK targeting and/or suppressing negative regulators of pp38α.
Medical subject headings
- JNK Mitogen-Activated Protein Kinases
- Pancreatic Neoplasms
- p38 Mitogen-Activated Protein Kinases